1.00
전일 마감가:
$1.01
열려 있는:
$1.01
하루 거래량:
88,831
Relative Volume:
0.70
시가총액:
$52.45M
수익:
-
순이익/손실:
$-51.47M
주가수익비율:
-1.00
EPS:
-1
순현금흐름:
$-47.50M
1주 성능:
-13.79%
1개월 성능:
-27.01%
6개월 성능:
-32.89%
1년 성능:
-44.13%
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
명칭
Pmv Pharmaceuticals Inc
전화
(609) 642-6664
주소
ONE RESEARCH WAY, PRINCETON
PMVP을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
PMVP
Pmv Pharmaceuticals Inc
|
1.00 | 52.45M | 0 | -51.47M | -47.50M | -1.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-11-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
2024-05-13 | 개시 | Craig Hallum | Buy |
2024-04-12 | 개시 | Jefferies | Buy |
2023-12-27 | 개시 | Ladenburg Thalmann | Buy |
2022-03-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
2021-09-22 | 업그레이드 | Goldman | Neutral → Buy |
2021-08-19 | 개시 | Oppenheimer | Perform |
2021-08-02 | 개시 | Guggenheim | Buy |
2021-07-29 | 개시 | H.C. Wainwright | Buy |
2020-10-20 | 개시 | BofA Securities | Buy |
2020-10-20 | 개시 | Cowen | Outperform |
2020-10-20 | 개시 | Evercore ISI | Outperform |
2020-10-20 | 개시 | Goldman | Neutral |
모두보기
Pmv Pharmaceuticals Inc 주식(PMVP)의 최신 뉴스
PMVP stock touches 52-week low at $1.01 amid market challenges - Investing.com Australia
PMV Pharmaceuticals stock hits 52-week low at $1.2 amid market shifts - Investing.com
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World
HC Wainwright Reiterates “Buy” Rating for PMV Pharmaceuticals (NASDAQ:PMVP) - Defense World
Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace
PMVP stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia
PMVP stock touches 52-week low at $1.2 amid market challenges By Investing.com - Investing.com South Africa
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing - Nasdaq
PMV Pharmaceuticals Reports Progress in Clinical Trials - TipRanks
PMV Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PMV Pharmaceuticals stock hits 52-week low at $1.32 By Investing.com - Investing.com South Africa
PMV Pharmaceuticals stock hits 52-week low at $1.32 - Investing.com
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference - The Manila Times
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights - GlobeNewswire
PMV Pharmaceuticals (PMVP) Expected to Announce Quarterly Earnings on Thursday - Defense World
3 US Penny Stocks To Consider In February 2025 - Simply Wall St
PMV Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Perceive Pharma: $15 Million (Series A) Raised For Advancing Ophthalmic Neuroprotection - Pulse 2.0
PMVP Stock Sees Surge of Approximately 2.86% in Last Five Days - Knox Daily
Catalio Capital Management Joins $15 Million Series A for Perceive Pharma - citybiz
Perceive Pharma Attracts $15M Series A Financing to Advance Ophthalmic Neuroprotection - PR Newswire
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Sees Significant Drop in Short Interest - MarketBeat
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results - br.ADVFN.com
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences - GlobeNewswire
PMVP's Top Executives Set to Reveal Latest Oncology Developments at Major Healthcare Conferences - StockTitan
US Penny Stocks To Watch In January 2025 - Simply Wall St
Assenagon Asset Management S.A. Reduces Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Barclays PLC Trims Stock Position in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Barclays PLC Trims Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat
Jane Street Group LLC Sells 89,957 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Jane Street Group LLC Sells 18,128 Shares of New Found Gold Corp. (NYSE:NFGC) - Defense World
PMV Pharmaceuticals stock hits 52-week low at $1.4 amid market challenges - Investing.com India
PMV Pharmaceuticals stock hits 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa
Barclays PLC Sells 434,704 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - Defense World
Barclays PLC Cuts Stock Holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) - MarketBeat
Kailera Therapeutics Appoints Laurie Stelzer as Chief Financial Officer - The Manila Times
PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials - GlobeNewswire
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial - Nature
Institutional investors may overlook Premier Investments Limited's (ASX:PMV) recent AU$278m market cap drop as long-term gains remain positive - Yahoo Finance
Pmv Pharmaceuticals Inc (PMVP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):